Fundamentals
Amgen, Inc. (NASDAQ:AMGN) has a history of exceeding street expectation. As the table below shows, the company has beaten estimates in the last four quarters. The street was expecting Amgen to post earnings of $1.84, but the companies exceed expectations with an EPS of $1.96. The revenues were $128 million short of consensus due to lower sales of Epogen, Enbrel and Denosumab.
| Earnings History | Jun 12 | Sep 12 | Dec 12 | Mar 13 |
|---|---|---|---|---|
| EPS Est | 1.54 | 1.47 | 1.38 | 1.84 |
| EPS Actual | 1.83 | 1.67 | 1.40 | 1.96 |
| Difference | 0.29 | 0.20 | 0.02 | 0.12 |
| Surprise % | 18.80% | 13.60% | 1.40% | 6.50% |
Source: Yahoo Finance
Despite its pipeline strength, Amgen, Inc. (NASDAQ:AMGN) is not safe from generic threat as a number of key patents are on the verge of expiration. The EPO market is on the verge of saturation with Roche’s Mircera and Teva’s biosimilar versions of Neupogen. The patent expiry of Zometa will also trouble the company in 2013. There are a number of Zometa generics already on the market with prices 20% to 40% lower as compared to the branded product.
Pipeline Strength
As the largest biotechnology company in the world, Amgen’s pipeline is strong, to say the least. It has more than 43 candidates in the pipeline, in various stages of clinical trials. The release of clinical data is a significant stock price catalyst for any biotechnology company. Amgen, Inc. (NASDAQ:AMGN) is set to release data on a number of Phase III trials in 2013. It has six assets in its bio-similar program, 2 in inflammation segment and four in oncology.
The following table represents a summary of some valuable pipeline updates from Amgen in 2013 and 2014:
| Product | Date | Object | Indication |
|---|---|---|---|
| AMG-145 | June 2013 | Phase II Study Part A data | Hyperlipidemia |
| AMG-386 | 2013 | Phase III data | Ovarian Cancer |
| T-VEC | 2013 | Phase III data | Advanced Melanoma |
| Brodalumab | 2014 | Phase III data | Psoriasis |
Valuations
Amgen, Inc. (NASDAQ:AMGN) has appreciated approximately 50% in the last one year. The company is trading at a forward P/E of 11.9x and 13% below mean sell side target price of $113. The company has barely managed to outperform the Amex Biotech Index. However, the returns have been much lower than Gilead Sciences, Inc. (NASDAQ:GILD). Gilead is the most comparable company to Amgen because it also has a steady stream of revenues and a exceptionally strong pipeline.
The performance of Amgen, Inc. (NASDAQ:AMGN) has been better than Pfizer Inc. (NYSE:PFE) . The analysis below shows that if we take into account the maturity of Pfizer’s pipeline and dividend payout, Amgen’s performance should have been even better.
The table below gives u a comparative analysis of Amgen’s valuations as compared to Gilead Sciences, Inc. (NASDAQ:GILD) and Pfizer Inc. (NYSE:PFE). Amgen is trading at a forward P/E of 11.9x which is lower than both competitors. The company has a higher P/S than Pfizer but almost half of Gilead Sciences, Inc. (NASDAQ:GILD). A higher P/S and lower P/E show that Amgen, Inc. (NASDAQ:AMGN) has much higher margins as compared to its competitors, showing the company’s ability to charge a premium price for its product. The biotechnology giant has an abysmal 5-year average revenue growth rate but the best EPS growth rate of 15.0% amongst peers.
